Monte Rosa Therapeutics, Inc. GLUE Accounts Payable

Accounts Payable at other companies

Bristol-Myers SquibbBMY

$4.16B-23.4%

Nurix Therapeutics, Inc.NRIX

$12.21M+105%

Kymera TherapeuticsKYMR

$8.92M+54.3%

Vor BiopharmaVOR

$1.04M-72.1%

BiohavenBHVN

$10.42M-45.6%

Nektar TherapeuticsNKTR

$10.03M-43.8%

FAQ

What is Monte Rosa Therapeutics, Inc.'s accounts payable?

Monte Rosa Therapeutics, Inc. (GLUE) reported accounts payable of $7.15M in Q2 2026.

How has Monte Rosa Therapeutics, Inc.'s accounts payable changed year-over-year?

Monte Rosa Therapeutics, Inc.'s accounts payable increased by 28.1% year-over-year, from $5.58M to $7.15M.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s accounts payable?

Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s accounts payable has grown at a -12.9% compound annual growth rate (CAGR), from $7.07M to $3.55M.

What does accounts payable mean?

Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.